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The treatment of advanced Hodgkin’s disease poses unique chal-
lenges for those involved in the design of randomized clinical
trials. The disease predominantly affects young adults, approx-
imately 70% of whom are likely to be cured by modern first 
line combination chemotherapy (Canellos et al, 1992). Late side-
effects of treatment, particularly gonadal toxicity and the risk of
secondary myelodysplasia and acute myeloid leukaemia (MDS/
AML), are major issues for long-term survivors. 
In view of the high response and cure rates, randomized trials in
this disease must recruit large numbers of patients to have
adequate statistical power. Attempts to improve response and
survival rates by intensifying initial chemotherapy must be
balanced against the potential for long-term toxicity. In view of the
effectiveness of salvage therapy, particularly high-dose therapy
and autologous stem cell transplantation (ASCT) (Linch et al,
1993; Sweetenham et al, 1997; Yuen et al, 1997; Lazarus et al,
1999) intensified initial therapy may only be appropriate for
patients with adverse prognostic factors at presentation. 
The stakes are high for a young adult with advanced Hodgkin’s
disease. When asked to participate in a clinical trial, the patient
must be reassured that this trial is asking a relevant question, that
his or her chances of long-term survival will not be compromised
by participating in the trial, and that the potential long-term con-
sequences of the treatment will be addressed. The results of 
the British National Lymphoma Investigation (BNLI)/Central
Lymphoma Group (CLG) randomized trial reported in this issue of
the British Journal of Cancer (Hancock et al, 2001) should be
judged against these criteria. This study was initiated in 1992, at
about the same time that Cancer and Leukemia Group B (CALGB)
reported the results of a randomized trial comparing ABVD
(doxorubicin, bleomycin, vinblastine, dacarbazine), MOPP
(mustine, vincristine, procarbazine, prednisone), and alternating
MOPP/ABVD in 361 patients (Canellos et al, 1992). Response,
failure-free and overall-survival rates were equivalent for ABVD
and MOPP/ABVD. Both were superior to MOPP alone. Since the
publication of this study, ABVD has been widely regarded as
‘standard’ chemotherapy for advanced Hodgkin’s disease. 
The BNLI/CLG trial compared an alternating ‘variant’ of
MOPP/ABVD, known as ChlVPP/PABIOE (chlorambucil, vin-
blastine, procarbazine, prednisone/prednisone, doxorubicin, bleo-
mycin, vincristine, etoposide) with PABIOE alone. The original
phase II multicentre trial of the ChlVPP/PABIOE regimen plus
radiotherapy reported 5 year FFS and OS rates of 68% and 78%
respectively (Cullen et al, 1994). These results are comparable to
MOPP/ABVD. 
The authors’ rationale for a randomized comparison of this
regimen with PABIOE alone was 2-fold. Firstly, the CALGB study
was relatively small and lacked sufficient power to confirm
ABVD as the optimal regimen. Therefore, they felt a further
comparison of an alternating regimen with an ‘ABVD-like’
regimen in a much larger trial was needed. Secondly, they justify
the use of PABIOE alone on the basis of its ‘similarity’ to ABVD.
However, as Table 1 shows, although 2 drugs are common to both
regimens, they differ markedly, not only in the constituent drugs,
but also in dose and scheduling. The assumption that the 2 regi-
mens are similar was therefore speculative and apparently not
supported by any phase II data demonstrating the efficacy of
PABIOE alone. In the absence of such data, it is not clear why the
authors felt that this regimen merited comparison in a large
randomized trial, particularly since the resulting trial had no recog-
nized standard arm. If ABVD had been chosen as the control arm
of this trial, the ChlVPP/PABIOE regimen would have been
assessed against an established standard, and the results of the
study would have been informative. The choice of PABIOE
resulted in a trial with little relevance to current therapy of
Hodgkin’s disease. This is particularly disappointing in view of the
large number of patients (almost 700) who participated. 
The overall survival (OS) for patients on both arms of this study
(91% at 3 years for ChlVPP/PABIOE and 85% at 3 years for
PABIOE) is comparable with many large clinical trials in
advanced Hodgkin’s disease. By contrast, the 3 year failure-free
survival (FFS) rate of 58% for PABIOE is markedly inferior to that
reported for ABVD in the CALGB trial. The poor outcome in
comparison with ChlVPP/PABIOE resulted in early closure of the
trial, although the interim analysis did not enable closure until
accrual was only 21 patients short of the planned total of 700. The
number of patients suffering from relapsed/progressive disease
was almost double for PABIOE compared with the alternating
regimen, and the number of patients treated with high-dose
therapy and ASCT as second-line therapy was also double on this
arm. Despite the apparent similarity of the ‘salvage’ strategy for
both arms of the trial, the OS for those initially randomized to
PABIOE is significantly lower than for the alternating regimen.
This suggests that PABIOE is not only inferior first-line
chemotherapy, but that its use may compromise the effectiveness
of second-line treatment. This is an important observation which
might be clarified if more details of second-line therapy were
available. 
The long-term toxicity of therapy is not addressed in this report.
Since the alternating arm of this trial is clearly superior, late 
toxicity has not been a major factor in determining the best
regimen. However, all trials in this disease should adopt the model
established by major trials groups such as the EORTC (European
Organization for Research and Treatment of Cancer) Lymphoma
Co-operative Group an the NCI Canada, in which collection of
long-term toxicity data is now routine. 
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progress, comparing ChlVPP/PABIOE with ABVD and a hybrid
regimen, ChlVPP/EVA (chlorambucil, vinblastine, procarbazine,
prednisone/etoposide, vincristine, doxorubicin) (Radford et al,
1995). Although the comparison of ChlVPP/PABIOE with a
recognized standard regimen is now in progress, the group may
now be asking the right question at the wrong time. New
approaches to the treatment of advanced Hodgkin’s disease have
developed since the CALGB trial was reported. The description
of a predictive model, based on clinical prognostic factors, has
provided an opportunity to construct a risk-stratified approach to
clinical trials (Hasenclever and Diehl, 1998). This is particularly
important in view of the introduction of novel, dose-intensive regi-
mens. These include the Stanford V (Bartlett et al, 1995) and dose-
escalated BEACOPP regimens (Diehl et al, 1998), both of which
are associated with significant short-term toxicity, but high-
response and progression-free survival rates in phase II studies.
The potential for long-term toxicity with Stanford V is thought to
be low – early results show high rates of normal male and female
reproductive function after completion of this therapy (Horning 
et al, 1998), and the risk for secondary MDS/AML is probably
low. Toxicity with escalated BEACOPP is more worrying – in the
latest report from the German Hodgkin’s Lymphoma Study Group
8 of 460 patients randomized to this regimen have developed
secondary AML/MDS (Diehl et al, 2000). However, the 3 year
FFS for BEACOPP was 89%, compared with only 70% for the
COPP/ABVD alternating regimen used in this trial. Most recent
results for the Stanford V regimen are very similar, with a 5-year
actuarial FFS of 89%. 
The results of these regimens are exciting, and require confir-
mation in randomized trials, compared with standard therapy. A
small randomized comparison of Stanford V with ABVD has
recently been completed, although results are not yet available. A
much larger comparison of these 2 regimens for ‘low-risk’ patients
with advanced Hodgkin’s disease is being performed in an inter-
group study in the USA. Comparison of BEACOPP with ABVD
will also be required to establish its true effectiveness. The assess-
ment of these regimens is likely to be a major emphasis of clinical
research in Hodgkin’s disease for the next few years. 
International collaboration will be required to perform clinical
trials of sufficient statistical power to determine whether these
new regimens represent true advances in treatment of Hodgkin’s
disease. Endpoints of these trials must include short- and long-term
toxicity, as well as failure-free and overall survival. Patients with
Hodgkin’s disease can then be reassured that they are participating
in trials which will answer relevant questions in a timely manner. 
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Table 1
ABVD PABIOE 
Doxorubicin 25 mg/m2 i.v. days 1 and 15 Doxorubicin 40 mg/m2 i.v. day 1 
Bleomycin 10 IU/m2 i.v. days 1 and 15 Bleomycin 10 IU/m2 i.v. days 1 and 8 (1st 4 cycles) 
Vinblastine 6 mg/m2 i.v. days 1 and 15 Vincristine 1.4 mg/m2 i.v. days 1 and 8 
Dacarbazine 375 mg/m2 i.v. days 1 and 15 Etoposide 200 mg/m2 p.o. daily for 3 days 
Treatment interval = 28 days Prednisolone 40 mg/m2 p.o. daily ´ 10 days 
Treatment interval = 21 days 